Retour

Explorez tous les épisodes du podcast Neurology Today in 5

Plongez dans la liste complète des épisodes de Neurology Today in 5. Chaque épisode est catalogué accompagné de descriptions détaillées, ce qui facilite la recherche et l'exploration de sujets spécifiques. Suivez tous les épisodes de votre podcast préféré et ne manquez aucun contenu pertinent.

Rows per page:

1–50 of 99

TitreDateDurée
Revised criteria for diagnosing MS, AI for alleviating administrative burden, neonatal neurocritical care as a growing subspecialty19 Dec 202400:05:20

In this week’s podcast, Neurology Today’s editor-in-chief highlights articles on proposed updated criteria for diagnosing MS before symptoms manifest, the use of large language models to address administrative burden with electronic medical records, and the growth of training programs in neonatal neurocritical care.

3-year outcomes for anti-NMDAR encephalitis, skin biopsies for diagnosis of human prion diseases, the career benefits of graduate degrees in public health and/or business administration05 Dec 202400:05:02

In this week’s podcast, Neurology Today’s editor-in-chief highlights articles on a study highlighting three-year outcomes for patients with anti-NMDAR encephalitis, an analysis comparing the diagnostic efficacy of skin biopsies vs. CSF tests for human prion diseases, and the ways in which a graduate degree in public health and/or business administration can shape career pathways for neurologists.  

Antihypertensive and reduced risk for epilepsy, first responders to 9-11 and early dementia risk, FDA approval of donanemab18 Jul 202400:05:17

In this week’s podcast, Neurology Today’s editor-in-chief discusses data on an angiotensin receptor for blocker for hypertension associated with reduced risk for epilepsy, a study finding first responders to 9-11 clean-up sites had an increased risk for early dementia, and dementia experts comment on approval of donanemab.

Rescue therapies when endovascular thrombectomy fails, the impact of first-seizure clinics on outcomes, AI and sleep neurology04 Jul 202400:05:10

In this week’s podcast, Neurology Today’s editor-in-chief discusses data on the effectiveness of rescue therapies when endovascular thrombectomy fails, how first-seizure clinics reduce hospitalizations, and AI’s use in sleep neurology.

When to withdraw life support for severe TBI, inflammatory markers score and stroke risk, application overload for neurology residency programs.20 Jun 202400:04:45

In this week’s podcast, Neurology Today’s editor-in-chief discusses a paper advising against prematurely withdrawing life support for severe TBI, data showing those with the highest composite score of inflammatory markers had a greater risk for stroke, original reporting stressing that residency programs and applicants need to adopt more strategic approaches to managing the overwhelming volume of applications.

This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.  

Code for ICH, new findings on Havana syndrome, distal symmetric polyneuropathy underdiagnosed in low income primary care clinics06 Jun 202400:05:14

In this week’s podcast, Neurology Today’s editor-in-chief discusses a push among neurocritical care experts to develop a code procedure for intracerebral hemorrhage, new findings showing people with Havana syndrome have functional neurologic disorder, and a study reporting distal symmetric polyneuropathy is more prevalent but less diagnosed in primary care clinics in low-income areas.  

This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.

Surgical removal of hematoma in ICH, disparities in neurodiagnosis for epilepsy, inequities among female neurology researchers16 May 202400:04:54

In this week’s podcast, Neurology Today’s editor-in-chief discusses a new study reporting better outcomes with surgical removal of hematoma in intracerebral hemorrhage, disparities in access to diagnosis and care for epilepsy, and the challenges that remain for women in neurology research.

Generative AI for personal statements, Match Day and neurology, AHS statement on CGRP-targeting therapies02 May 202400:04:48

Neurology Today Editor-in-Chief Joseph E. Safdieh, MD, FAAN, highlights new articles that discuss program directors’ response to the use of generative AI for personal statements, the good news for neurology based on the 2024 Match Day, and the AHS statement on CGRP-targeting therapies as a game changer for migraine treatment.

ME/CFS and long COVID; negative outcomes for ALS drug; donanemab18 Apr 202400:04:31

Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that explores an association between myalgic encephalomyelitis/chronic fatigue and long COVID; negative phase 3 findings on AMX0035 for ALS, and the pending approval of donanemab for Alzheimer’s disease.

BTK inhibitors for MS, lecanemab, neurologic adverse effects and COVID vaccine04 Apr 202400:04:24

Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that casts doubt on the future of BTK inhibitors for MS, an assessment of the cost-effectiveness of lecanemab, and findings that COVID vaccines are not significantly associated with adverse neurologic events.

SARS-CoV-2 and dopamine neurons, valproate risks for men, neurologists on locum tenens21 Mar 202400:04:38

Neurology Today Editor-in-Chief Joseph E. Safdieh, MD, FAAN, highlights new stories reporting on the impact of SARS-CoV2 on dopamine neurons, a European Medicines Agency warning about valproate risks for men, and neurologists on the pros and cons of working locum tenens.

AI and 911 stroke detection, iatrogenic Alzheimer’s and human growth hormone, seizure dogs and refractory epilepsy07 Mar 202400:04:38

Neurology Today Editor-in-Chief Joseph E. Safdieh, MD, FAAN, highlights new stories reporting on the use of AI in EMS systems for stroke detection, the association between human growth hormone and iatrogenic Alzheimer’s, and seizure dogs for refractory epilepsy.

Cardiovascular effects of antiseizure therapies, social determinants of health on children with MS, coverage for blood-based biomarkers for Alzheimer’s21 Nov 202400:04:40

In this week’s podcast, Neurology Today’s editor-in-chief highlights articles on the higher risk for cardiovascular effects with certain antiseizure therapies on adults with epilepsy, the impact of social determinants of health on children with MS, and the status of coverage for blood-based tests for Alzheimer’s disease.

Biomarker for migraine; posterior cortical atrophy gene therapy for neuromuscular disorders12 Feb 202400:04:30

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses a new study showing retinal vascular perfusion as a migraine biomarker, clinical and pathophysiological correlates of posterior cortical atrophy, and advances in gene therapies for neuromuscular disorders.

Cerebral amyloid angiopathy and nontraumatic subdural hemorrhage, AI for neurology boards, weight loss drugs and neurologic conditions25 Jan 202400:04:39

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies showing the cerebral amyloid angiopathy as a risk factor for nontraumatic subdural hemorrhage, AI beats humans in neurology-like boards, and the impact of popular weight loss drugs on neurologic conditions.

Rising incidence of Creutzfeldt-Jakob disease, therapy for prodromal migraine, neurotrauma of blast injury16 Jan 202400:04:18
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies showing the rising incidence of Creutzfeldt-Jakob disease, an effective therapy for prodromal migaine, and neuroinflammation in military personnel exposed to blast injury.
DBS and cognition in severe TBI, in utero exposure to antiseizure drugs, best advances of 202302 Jan 202400:04:08

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies on the impact of deep brain stimulation on cognition in severe traumatic brain injury and how adaptive functioning is impacted in children exposed to antiseizure drugs in utero, and the editorial board’s picks for the best advances of 2023.

Parkinson’s and suicide risk; biomarkers and underrepresentation in Alzheimer’s trials, immune system changes in ALS and Parkinson’s.21 Dec 202300:04:36

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies showing double the suicide risk among Parkinson’s patients; underrepresentation of non-White people in Alzheimer’s trial related to biomarker eligibility; early immune systems changes may play early role in ALS and Parkinson's.

Serotonin and long COVID, Afib detected 3 years after stroke, Medicare on PET amyloid scans07 Dec 202300:04:43

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies showing serotonin depletion associated with long COVID; implantable cardiac monitors detect Afib 3 years post-stroke; and what Medicare’s decision to cover PET amyloid scans means for neurologists.

A promising drug for refractory epilepsy; adverse childhood events and headache disorders; pathological engulfment by microglia in dementia.16 Nov 202300:04:49

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies on a promising potassium channel opener for refractory epilepsy; the impact of adverse childhood events in headache disorders; and excessive engulfment by microglia/astroctyes in dementia.

Blood transfusions and spontaneous intracerebral hemorrhages, long distance travel to neurologists, biomarkers for Parkinson’s disease02 Nov 202300:04:43

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new research on the risk of spontaneous intracerebral hemorrhages after blood transfusions; the burden of long distance travel to see neurologists; and two promising biomarkers for early diagnosis of Parkinson’s disease.

Blood pressure and endovascular therapy, cutbacks in neurology CME, blood test for Alzheimer’s19 Oct 202300:04:47

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new research on blood pressure targets for stroke after endovascular therapy, changing policies on CME, and a direct-to-consumer blood test for Alzheimer’s disease.

Football and Parkinson’s, deep brain stimulation for stroke recovery, neuroprostheses for anarthric patients05 Oct 202300:04:47

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new research on football and the risk for Parkinson’s disease, the potential of deep brain stimulation for recovery from stroke, and neuroprostheses for patients with anarthria.

Fever prevention and stroke, environmental toxins and Parkinson’s, cholesterol overload and ALS progression07 Nov 202400:04:20

In this week’s podcast, Neurology Today’s editor-in-chief highlights articles on fever prevention and stroke outcomes, the impact of air pollution and other environmental toxins on Parkinson’s, and the role of cholesterol overload in ALS progression and disease risk.

Medicare coverage of carotid stenting, disparities in vulnerable neuro-oncology patients, optical EMG for neuromuscular disorders.21 Sep 202300:05:12

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses the Medicare’s proposed coverage of carotid stenting in asymptomatic patients,neuro-oncologists’ perspectives on a federal initiative to target persistent poverty in vulnerable patients, and the technological promise of a new optical EMG for neuromuscular disorders.

Endovascular treatment and intracranial tumors; guideline on IVIG use for neuromuscular disorders, pros and cons of donanemab.07 Sep 202300:05:27

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses research that assesses the safety of endovascular treatment post-stroke for people with intracranial tumors, the AANEM guideline on IVIG use for neuromuscular disorders, and the latest data on donanemab.

Oral health and cognitive decline; managing first-ever sleep seizures; growth of concierge neurology.17 Aug 202300:04:56

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses studies that associate poor oral health and risk for cognitive decline and how to manage first-ever sleep seizures that recur as well as the growth of concierge neurology.

Gene variants and MS severity, AI and EEG reads, neuroprotective agent for ischemic stroke03 Aug 202300:05:43

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses studies that identify gene variants associated with MS severity/progression, an AI program that read EEGs accurately, and butylphthalide as a promising neuroprotective agent for ischemic stroke.

Antigen tolerance in mouse MS model, epileptiform activity and ICU outcomes, agent slows gliomas.20 Jul 202300:05:12

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses a novel therapeutic approach that induced antigen tolerance in an MS mouse model, the association between epileptiform activity and ICU outcomes, and an agent, vorasidenib, that slows low-grade gliomas.

Gout and risk of neurodegenereative diseases, Tenecteplase compared with warfarin, cognitive decline after heart attack06 Jul 202300:05:27

In this week’s podcast, Neurology Today’s editor-in-chief discusses the association between gout and neurodegenerative diseases, tenecrteplase vs.warfarin for acute stroke, expedited cognitive decline after a heart attack.

Antipsychotic for dementia-related agitation, contaminated water at Camp Lejeune associated with elevated risk for Parkinson’s, gene variant confers resilience against autosomal dominant Alzheimer’s.15 Jun 202300:05:29

In this week’s podcast, Neurology Today’s editor-in-chief discusses the FDA approval of an antipsychotic for agitation in dementia, elevated risk for Parkinson’s in Camp Lejeune Marines exposed to contaminated water, a gene variant delays the onset of symptoms in man with autosomal dominant Alzheimer’s.

This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.

OnabotulinumtoxinA for pregnant women with migraine, adderrall shortage, AI for epilepsy01 Jun 202300:05:12

In this week’s podcast, Neurology Today’s editor-in-chief discusses a study on the safety of omnabotuliumtoxinA on pregnant women with migraine, the impact of the Adderall shortage on patients with ADHD and narcolepsy, and the state of AI for epilepsy. This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.

This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.

Assay detects Parkinson’s before symptom onset; life stressors in pregnant women with epilepsy; role of inflammation in NORSE18 May 202300:05:23

In this week’s podcast, Neurology Today’s editor-in-chief discusses a new study reporting a gene assay detected Parkinson’s before symptoms onset, life stressors greatly impact women with epilepsy during pregnancy; the role of inflammation in new-onset refractory status epilepticus.

 This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.

Anticoagulants for patients with dementia and Afib, tau levels in women taking hormone replace therapy, neurohumanities programs for neurology residents.04 May 202300:05:56

In this week’s podcast, Neurology Today’s editor-in-chief discusses a new study finding anticoagulants are safe for patients with atrial fibrillation and dementia, women on hormone replacement therapy had higher tau levels, and neurology residents are participants in humanities programs to foster wellness.  

Blood test for ALS, new migraine target reduces headache days, latest data on eculizumab for neuromyelitis optica spectrum disorder17 Oct 202400:04:41

In this week’s podcast, Neurology Today’s editor-in-chief highlights articles on the potential of a new blood biomarker for ALS, a PACP-targeted migraine therapy, and a real-world review of data on eculizumab for neuromyelitis optica spectrum disorder.

This Podcast is being Sponsored by LocumTenens.com

Fertility treatments for women with MS, stroke systems of care, ravalizumab for NMOSD20 Apr 202300:05:59

In this week’s podcast, Neurology Today’s editor-in-chief discusses a new study finding fertility treatments did not lead to MS relapses for women, a AHA consensus statement that finds stroke systems need improvement, and ravalizumab at less frequent doses was effective for neuromyelitis optica spectrum disorder.

Intranasal CGRP for migraine, ultrasound ablation for Parkinson’s disease, novel therapeutic pathway for Duchenne muscular atrophy.06 Apr 202300:06:06

In this week’s podcast, Neurology Today’s editor-in-chief discusses the newly approved zavegepant for migraine, the potential/caveats of ultrasound ablation for Parkinson’s disease, the transational potential of a new therapeutic target for Duchenne muscular atrophy.

Antipsychotics and dementia risk; biomarkers for lecanemab eligibility; trial of difelikefalin for neurogenic itch in notaliga paresthetica.16 Mar 202300:06:07

In this week’s podcast, Neurology Today’s editor-in-chief discusses the increased use of antipsychotics during the pandemic and an associated greater risk for dementia, determining the best biomarkers when considering lecanemab for Alzheimer’s, and a novel approach for managing uncomfortable neuropathic symptoms.

Pregnancy-associated stroke outcomes; a robotic device for shoulder movement in ALS; non-invasive neurostimulation for refractory seizures. 02 Mar 202300:05:55

In this week’s podcast, Neurology Today’s editor-in-chief discusses long-term adverse outcomes from pregnancy-associated stroke, a robotic device to assist shoulder movement in ALS, and the promise of neurostimulation for refractory seizures in the ICU.  

Acute infections and increased risk for dementia, alternatives to CPAP for sleep apnea; the legacy of Dr. Ralph Sacco. 16 Feb 202300:05:30

In this week’s podcast, Neurology Today’s editor-in-chief discusses the associated risk between acute infections and dementia; alternative therapies to CPAP for sleep apnea; and Dr. Ralph Sacco’s impact on the field.  

IV thrombolysis for large vessel occlusion; impact of mindfulness, exercise on cognition;new brain layer in subarachnoid space.02 Feb 202300:05:31

In this week’s podcast, Neurology Today’s editor-in-chief discusses the report on outcomes of IV thrombolysis for large vessel occlusions; the discovery of a new brain layer in the subarachnoid space; and the impact of mindfulness and exercise on cognition.

Best advances of 2022, misdiagnosed autoimmune encephalitis, inflation his neurology private practice19 Jan 202300:05:50

In this week’s podcast, Neurology Today’s editor-in-chief discusses the report on misdiagnosis of autoimmune encephalitis, inflationary times for neurologists in private practice, and the editorial board picks for best advances in 2022.

Spinal cord stimulation for chronic pain, disparities in brain age by race/ethnicity, careers in teleneurology04 Jan 202300:05:04

In this week’s podcast, Neurology Today’s editor-in-chief discusses a comparison of spinal cord stimulation with medical management for chronic pain, earlier brain aging in Black people, and the pros/cons of working for teleneurology companies.

Rituximab for MS, food security and cognition, in utero treatment for Pompe disease15 Dec 202200:05:56

In this week’s podcast, Neurology Today’s editor-in-chief discusses why MS specialists advocate for rituximab for MS, how food security may relate to cognition, and a novel in utero therapy for Pompe diseasea.

Modifiable risk factors for monogenic stroke, health care systems prepare for wave of new Alzheimer’s therapies, criteria for selecting neurology residents01 Dec 202200:05:15

In this week’s podcast, Neurology Today’s editor-in-chief discusses modifiable risk factors for monogenic stroke, what health care systems need to do to prepare for new Alzheimer’s therapies, and criteria program directors apply in selecting neurology residents.

Eastern equine encephalitis, systems for anti-amyloid therapies, new protocol for eye stroke03 Oct 202400:04:32

In this week’s podcast, Neurology Today’s editor-in-chief highlights articles on Eastern equine encephalitis relief, systems developed to meet demand for anti-amyloid therapies, and a new protocol for timely diagnosis and treatment for eye stroke in the emergency department.

This Podcast is being Sponsored by LocumTenens.com

Revascular therapies for stroke patients with COVID, dementia and suicide risk, hyperbaric oxygen therapy for concussion in children.17 Nov 202200:05:13

In this week’s podcast, Neurology Today’s editor-in-chief discusses data suggesting revascular therapies are safe for patients with stroke and COVID, dementia is associated with increased suicide risk, and the potential of hyperbaric oxygen therapy for children with concussion.

Allergies and dementia risk, folic acid and risk of cancer in children of women with epilepsy, climate change and neurologic disorders.03 Nov 202200:05:47

In this week’s podcast, Neurology Today’s editor-in-chief discusses data suggesting allergic disease is associated with an increased risk of dementia, an increased risk of cancer in children born to women with epilepsy who took high-dose folic acid in pregnancy, and the impact of climate change on people with neurologic disorders.

Vamorolone for DMD, aquaporin protein and amyloid clearance, monkey pox-associated neurologic events.20 Oct 202200:05:28

In this week’s podcast, Neurology Today’s editor-in-chief discusses data suggesting vamorolone as an alternative to corticosteroids for Duchenne muscular dystrophy, how an aquaporin protein promotes amyloid clearance, and neurologic events associated with monkeypox virus.

Chronic kidney disease and risk for intracerebral hemorrhage, gonadotropic replacement and cogntion in Down syndrome, how to distinguish polio from other viruses06 Oct 202200:05:14

In this week’s podcast, Neurology Today’s editor-in-chief discusses new findings on chronic kidney disease and risk for intracerebral hemorrhage, the potential of  gonadotropic replacement for improving cognition in Down syndrome, and distinguishing polio from acute flaccid myelitis and other viruses.

© My Podcast Data